Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease Read more about Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
Agios Reports Business Highlights and Third Quarter 2020 Financial Results Read more about Agios Reports Business Highlights and Third Quarter 2020 Financial Results
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting Read more about Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020 Read more about Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 Read more about Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia Read more about Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
Q3 2020 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q3 2020 Agios Pharmaceuticals Inc Earnings Conference Call
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients Read more about Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs Read more about Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs